The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Ocular Gene Therapy: From Fantasy to Foreseeable Reality
Abstract
THIS ISSUE of theArchivescommemorates the 40th anniversary of the publication of Watson and Crick's 1 classic paper on the structure of DNA. In 1953, gene therapy was mentioned only in the realm of science fiction. Now, a mere 40 years later, gene therapy has become a reality. 2 A number of clinical trials are already in progress, and the number of proposed trials is increasing almost daily. 2-5 Current trials involve diseases as diverse as severe combined immunodeficiency, cancer, and cystic fibrosis. Although to date none of these trials involves the eye, this situation is sure to change in the near future. (In one sense, ocular gene therapy is already a reality. The murine retinal degeneration [ rd ] and retinal degeneration slow [ rds ] mutations have been rescued using transgenic mouse technology. 6,7 However, transgenesis involves germ line transformation and is not directly applicable to human gene therapy.) Genetic disease
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“implying that the underlying disease should also be considered a factor when assessing the risk of inflammation.80,81,109”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [109]
In the citing paper
“The OPTIC trial, which used the same vector type in neovascular AMD patients, did also show a dose dependent inflammatory response but much less in severity when compared with INFINITY trial”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [109]
Citations
Cites
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid
WATSON, J. D., & CRICK, F. H. C. (1953) · Nature · doi:10.1038/171737a0 · Cited by 13,584
The Basic Science of Gene Therapy
Mulligan, R. C. (1993) · Science · doi:10.1126/science.8493530 · Cited by 1,741
A point mutation of the rhodopsin gene in one form of retinitis pigmentosa
Dryja, T. P., McGee, T. L., Reichel, E., Hahn, L. B., Cowley, G. S., Yandell, D. W., Sandberg, M. A., & Berson, E. L. (1990) · Nature · doi:10.1038/343364a0 · Cited by 1,072
Human gene therapy comes of age
Miller, A. D. (1992) · Nature · doi:10.1038/357455a0 · Cited by 908
McLaughlin, M. E., Sandberg, M. A., Berson, E. L., & Dryja, T. P. (1993) · Nature Genetics · doi:10.1038/ng0693-130 · Cited by 596
A model system for in vivo gene transfer into the central nervous system using an adenoviral vector
Davidson, B. L., Allen, E. D., Kozarsky, K. F., Wilson, J. M., & Roessler, B. J. (1993) · Nature Genetics · doi:10.1038/ng0393-219 · Cited by 575
Transfer of a foreign gene into the brain using adenovirus vectors
Akli, S., Caillaud, C., Vigne, E., Stratford-Perricaudet, L. D., Poenaru, L., Perricaudet, M., Kahn, A., & Peschanski, M. R. (1993) · Nature Genetics · doi:10.1038/ng0393-224 · Cited by 532
Mutations within the Rhodopsin Gene in Patients with Autosomal Dominant Retinitis Pigmentosa
Dryja, T. P., McGee, T. L., Hahn, L. B., Cowley, G. S., Olsson, J. E., Reichel, E., Sandberg, M. A., & Berson, E. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231903 · Cited by 501
Wagner, E., Zatloukal, K., Cotten, M., Kirlappos, H., Mechtler, K., Curiel, D. T., & Birnstiel, M. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.6099 · Cited by 481
Rhodopsin mutations in autosomal dominant retinitis pigmentosa.
Sung, C. H., Davenport, C. M., Hennessey, J. C., Maumenee, I. H., Jacobson, S. G., Heckenlively, J. R., Nowakowski, R., Fishman, G., Gouras, P., & Nathans, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6481 · Cited by 461
Cited by
TUNEL-Positive Ganglion Cells in Human Primary Open-angle Glaucoma
Kerrigan, L. A. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100160201010 · Cited by 465
Self-citationKumar, R., Chen, S., Scheurer, D., Wang, Q.-L., Duh, E. J., Sung, C.-H., Rehemtulla, A., Swaroop, A., Adler, R., & Zack, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.47.29612 · Cited by 160
Self-citationApoptosis in ocular disease: a molecular overview
Nickells, R. W., & Zack, D. J. (1996) · Ophthalmic Genetics · doi:10.3109/13816819609057889 · Cited by 125
Self-citationAdler, R. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100130075012 · Cited by 77
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“The OPTIC trial, which used the same vector type in neovascular AMD patients, did also show a dose dependent inflammatory response but much less in severity when compared with INFINITY trial, implying that the underlying disease should also be considered a factor when assessing the risk of inflammation.(80,81,109) Few…”
Result
Metadata
- Authors
- Zack, D. J.
- Corresponding author
- Zack, Donald J.
- ORCID
- Zack, Donald J.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 1993-11-01
- Volume
- 111
- Issue
- 11
- Pages
- 1477
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2047079620
- Cited by
- 19
- References
- 30
- Citations by year
- 2022: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- ocular gene therapy, retinal degeneration, rd mouse, transgenic rescue, hereditary eye disease, history of gene therapy
- MeSH terms
- Animals, Eye Diseases, Forecasting, Humans, Molecular Biology, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ocular Gene Therapy: From Fantasy to Foreseeable Reality. https://app.cochat.ai/papers/10.1001/archopht.1993.01090110043019
- The paper
- Zack, D. J. (1993). Ocular Gene Therapy: From Fantasy to Foreseeable Reality. Archives of Ophthalmology. https://doi.org/10.1001/archopht.1993.01090110043019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.